FDA Approves Gilead’s New HIV Treatment For Heavily Treated With Multi-Drug Resistant Patients – Gilead Sciences (NASDAQ:GILD)
[ad_1] The FDA has approved Gilead Sciences Inc’s GILD Sunlenca (lenacapavir), in combination with another antiretroviral (s) (ARV), for HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection. …